Loading…
Employees: 13,000
Size Regis Healthcare (REG.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $1.05B, the 175th largest of 316 Australia companies the cockpit tracks. Shares closed at A$5.01 on 6 Nov 2026.
Performance Over six months the shares fell 17.3%, against +6.3% for the median peer and +4.1% for the Australia market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +6.7%); the operating margin is 3.8% (peer median 7.2%).
Valuation It trades at 25.1× forward earnings against a peer median of 18.6× (6th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$1.34B | A$1.34B | A$1.15B | A$1.01B | A$771M |
| Revenue growth | — | +17% | +15% | +30% | — |
| Gross profit | A$153M | A$153M | A$141M | A$39.0M | -A$3.78M |
| EBITDA | A$107M | A$107M | A$101M | A$83.6M | A$50.1M |
| Net income | A$55.7M | A$55.7M | A$49.0M | -A$21.4M | -A$28.5M |
| Free cash flow | A$194M | A$194M | A$220M | A$187M | A$53.7M |
| Capital expenditure | A$142M | A$142M | A$86.5M | A$65.7M | A$51.4M |
| Total debt | n/a | A$3.99M | A$5.11M | A$3.84M | A$71.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REG.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.7% | +0.1% | 4th highest of 21 |
| 6-month return | -17.3% | +6.3% | 4th lowest of 21 |
| Distance from 52-week high | -38.9% | -20.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +16.6% | +6.7% | 7th highest of 21 |
| Operating margin | 3.8% | 7.2% | 7th lowest of 21 |
| Forward P/E | 25.1× | 18.6× | 6th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 14.6% | 9.6% | 8th most demanding of 17 |
| Growth delivered (Del g) | +14.4% | +11.5% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | +0.2 pp | -0.4 pp | 8th most demanding of 17 |
| EV / EBITDA | 12.6× | 10.1× | 7th most expensive of 17 |
| Net debt / EBITDA | -1.6× | 3.3× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |